溴隐亭治疗垂体催乳素腺瘤的效果

摘要
图/表
参考文献(22)
相关文章 (15)

全文: PDF (0 KB) HTML (46 KB)
输出: BibTeX | EndNote (RIS)

摘要目的分析溴隐亭治疗垂体催乳素（PRL）腺瘤的使用方法和效果。方法选取2014年6月～2016年6月收治的垂体PRL腺瘤患者共47例为研究对象，其中垂体微腺瘤（肿瘤直径≤10 mm）27例，垂体大腺瘤（肿瘤直径＞10 mm）20 例；25μg/L≤PRL＜100 μg/L 者 5 例，100 μg/L≤PRL＜200 μg/L 者 22 例，PRL≥200 μg/L 者 20 例。患者确诊后立即开始服用溴隐亭治疗。定期复查血清PRL水平和进行垂体MRI增强检查。分析治疗前后PRL水平和肿瘤大小的改变，并监测患者用药期间出现的不良反应，及时调整治疗方案。结果溴隐亭治疗后，3例患者出现严重的不良反应而更换为卡麦角林治疗。在持续服用溴隐亭药物治疗的44例患者中，症状好转率为70.5%。不同的肿瘤大小和不同PRL水平的治疗效果差异均无统计学意义（P＞0.05）。治疗前后肿瘤直径变化差异有统计学意义（P＜0.05）。36.2%（17例）的患者在服药期间出现不同程度的不良反应，多数可以逐渐耐受。结论溴隐亭对垂体PRL腺瘤患者的高PRL血症和肿瘤大小均有显著的治疗效果，但治疗期间可存在多种不良反应，治疗剂量应个体化。治疗无效的患者应首选更换为其他多巴胺受体激动剂。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张芳芳
	章江南
	林兰梅
	黄银兴

关键词 ：溴隐亭, 垂体催乳素腺瘤, 催乳素, 多巴胺受体激动剂, 妊娠

Abstract：ObjectiveTo analyze the usage and effect of Bromocriptine treating pituitary prolactinoma.Methods47 patients with pituitary prolactinoma treated from June 2014 to June 2016 were selected as the subjects.Among them,there were 27 patients with pituitary microadenoma(tumor diameter≤10 mm),20 patients with pituitary macroadenoma(tumor diameter＞10 mm);there were 5 cases with 25 μg/L≤PRL＜100 μg/L,22 cases with 100 μg/L≤PRL＜200 μg/L,20 cases with PRL≥200 μg/L.After the patients were diagnosed,they are treated with Bromocriptine immediately.Serum prolactin level was regularly reviewed and pituitary enhanced MRI scan was conducted.PRL level and tumor size change were analyzed before and after treatment and the adverse reactions during the period of medication were monitored,and the treatment plan was adjusted in time.ResultsAfter Bromocriptine treatment,3 patients had severe adverse reactions and were replaced with Cabergoline.Among 44 patients who continued to take Bromocriptine medication,the symptom improvement rate was 70.5%.There was no significant difference in the therapeutic effect between different tumor size and different PRL level(P＞0.05).The changes of tumor diameter before and after treatment were statistically significant(P＜0.05).36.2%(17 patients)of patients in the medication had varying degrees of adverse reactions,the majority could be gradually tolerated.ConclusionBromocriptine has a significant therapeutic effect on hyperprolactinemia and tumor size in patients with pituitary prolactinoma,but there are several adverse reactions during treatment,and the therapeutic dose should be individualized.Patients with ineffective treatment should be preferred to replace the other dopamine receptor agonists.

Key words： Bromocriptine Pituitary prolactinoma Prolactin Dopamine agonists Pregnancy

基金资助:南京军区福州总医院青年育才项目（2014Q32）

通讯作者: 黄银兴（1980－），男，硕士，主治医师，主要从事垂体腺瘤的临床与基础研究

引用本文:

张芳芳；章江南；林兰梅；黄银兴. 溴隐亭治疗垂体催乳素腺瘤的效果[J]. 中国当代医药, 2017, 24(29): 11-14.
ZHANG Fang-fang；ZHANG Jiang-nan；LIN Lan-mei；HUANG Yin-xing. Clinical effect of Bromocriptine treating pituitary prolactinoma. 中国当代医药, 2017, 24(29): 11-14.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2017/V24/I29/11

[5]	Klibanski A.Prolactinomas[J].N Engl J Med，2010，362（13）：1219-1226.
[1]	Gillam MP，Molitch ME，Lombardi G，et al.Advances in the treatment of prolactinomas[J].Endocr Rev，2006，27（5）：485-534.
[2]	曹英肖，王风聚，刘振波.术前溴隐亭治疗对垂体催乳素腺瘤手术的影响[J].中华神经外科杂志，2013，29（7）：738-740.
[3]	GlezerA，BronsteinMD.Prolactinomas[J].EndocrinolMetabClin North Am，2015，44（1）：71-78.
[4]	覃刚.月经异常的育龄期女性中高泌乳素血症的发病情况分析[J].中国当代医药，2012，19（31）：58-59.
[6]	Casanueva FF，Molitch ME，Schlechte JA，et al.Guidlines of the pitutary society for the diagnosis and management of prolactinomas[J].Clin Endocrinol（Oxf），2006，65 （2）：265-273.
[7]	陈玉霞，刘秋艳.女性高泌乳素血症不孕152例临床分析[J].中国医药导报，2007，4（13）：139-140.
[8]	Tirosh A，Shimon I.Current approach to treatments for prolactinomas[J].Minerva Endocrinol，2016，41（3）：316-323.
[9]	Passos VQ，Souza JJ，Musolina NR，et al.Long-term followup of prolactinomasLnormoprolactinemia after bormocriptine withdrawal[J].J Clin Endocrinol Metab，2002，87（8）：3578-3582.
[10]	Margarida T，Pedro S，Davide C，et al.Prolactinoma management：preidctors of remission and recurrence after dopamine agonists withdrawal[J].Pituitary，2017，20（4）：464-470.
[11]	Sean N，Victoria S，Niki K.Treating prolactinomas with dopamine agonists：always worth the gamble[J].Endocrine，2016，51（2）：205-210.
[12]	Kepenekian L，Cebula H，Castinetti F，et al.Long-term outcome of macroprolactinomas[J].Ann Endocrinol （Paris），2016，77（6）：641-648.
[13]	Shimon I，Sosa E，Mendoza V，et al.Giant prolactinomas larger than 60 mm in size：a cohort of massive and aggressive prolactin-secreting pituitary adenomas[J].Pituitary，2016，19（4）：429-436.
[14]	Akin S，Isikay I，Soylemezoglu F，et al.Reasons and results ofendoscopicsurgeryforprolactinomas：142surgicalcases[J].Acta Neurochir （Wien），2016，158（5）：933-942.
[15]	Molitch ME.Pharmacologic resistance in prolactinama patients[J].Pituitary，2005，8（1）：43-52.
[16]	中国垂体腺瘤协作组.中国垂体催乳素腺瘤诊治共识（2014版）[J].中华医学杂志，2014，31（94）：2406-2411.
[17]	Maiter D，Primeau V.2012 update in the treatment of prolactinomas[J].Ann Endocrinol，2012，73（2）：90-98.
[18]	贺绍敏，杨娅丽.溴隐亭联合大剂量维生素B6治疗高泌乳血症的临床疗效观察[J].中国当代医药，2013，20（6）：96-97.
[19]	Maiter D.Prolactinoma and pregnancy：from the wish of conception to lactation[J].Ann Endocrinol，2016，77（2）：128-134.
[20]	Chen H，Fu J，Huang W.Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history[J].Cochrane Database Syst Rev，2016，7：CD008883.
[21]	Melmed S，Casanueva FF，Hoffman AR，et al.Diagnosis and treatment of hyperprolactinemia：an Endocrine Society clinical practice guideline[J].J Clin Endocrinol Metab，2011，96（2）：273-288.
[22]	Dogansen SC，Selcukbiricik OS，Tanrikulu S，et al.Withdrawal of dopamine agonist therapy in prolactinomas：in which patients and when[J].Pitutary，2016，19（3）：303-310.